Bard Pharmaceuticals Ltd.

a. To study the pharmacokinetic properties of oxycodone, naloxone and their metabolites in Chinese patients. b. To evaluate the drug dose-exposure relationship after a single administration of oxycodone-naloxone sustained-release tablets.

Evaluation of the efficacy of oxycodone/naloxone extended-release tablets in improving constipation symptoms in patients with moderate to severe non-cancer pain, as measured by the bowel function index (BFI) score, compared with oxycodone extended-release tablets alone

The bowel function index was used to evaluate the improvement of constipation symptoms of subjects after receiving oxycodone/naloxone sustained-release tablets. 2. The clinical non-inferiority of oxycodone/naloxone compared with oxycodone in the treatment of chronic cancer pain was verified. The efficacy of non-inferiority was evaluated by the subjects recording the brief pain questionnaire.